China's Kelun Biotech nets over $77m funding led by CMC-SDIC Capital

Kelun Biotech, a subsidiary of Shenzhen-listed Kelun Pharmaceutical, has secured over 500 million yuan ($77 million) in fresh funding led by CMC-SDIC Capital, a fund co-launched by state-backed China Merchants Capital and SDIC, the lead investor announced on Thursday.